Literature DB >> 28084148

Does Body Mass Index Predict Premature Cardiomyopathy Onset for Duchenne Muscular Dystrophy?

Meghann McKane1, Jonathan H Soslow1, Meng Xu2, Benjamin R Saville2, James C Slaughter2, W Bryan Burnette3, Larry W Markham1.   

Abstract

Duchenne muscular dystrophy leads to cardiomyopathy. The objective of this study was to estimate the association of body mass index with cardiomyopathy onset. Cardiomyopathy was defined as left ventricular ejection fraction <55% or left ventricular fractional shortening <28%. Overall, 48% met the criteria for cardiomyopathy. We were unable to demonstrate an association between body mass index Z score and age of cardiomyopathy onset (hazard ratio 0.79, 95% confidence interval 0.57-1.11, P = .17) after adjusting for covariates. Duration of corticosteroid use ( P = .01), but not loss of ambulatory ability ( P = .47), was associated with age of cardiomyopathy onset. We were unable to detect a significant difference in median body mass index Z scores in corticosteroid-treated boys compared with corticosteroid-naïve boys (1.11, 95% confidence interval 0.25-1.95, vs 1.05, 95% confidence interval 0.01-1.86, P = .69). No association was detected between the body mass index Z scores of Duchenne muscular dystrophy subjects and age of cardiomyopathy onset.

Entities:  

Keywords:  Duchenne muscular dystrophy; body mass index; cardiomyopathy

Mesh:

Year:  2017        PMID: 28084148      PMCID: PMC5352486          DOI: 10.1177/0883073816687422

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  24 in total

1.  Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit.

Authors:  Léonie Martigne; Julia Salleron; Michèle Mayer; Jean-Marie Cuisset; Alain Carpentier; Véronique Neve; Vincent Tiffreau; Dominique Guimber; Frédéric Gottrand
Journal:  Br J Nutr       Date:  2011-01-28       Impact factor: 3.718

2.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

3.  Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy.

Authors:  Tamara O Thomas; Thomas M Morgan; William B Burnette; Larry W Markham
Journal:  Pediatr Cardiol       Date:  2012-03-21       Impact factor: 1.655

4.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  Body composition and energy expenditure in Duchenne muscular dystrophy.

Authors:  M C Zanardi; A Tagliabue; S Orcesi; A Berardinelli; C Uggetti; A Pichiecchio
Journal:  Eur J Clin Nutr       Date:  2003-02       Impact factor: 4.016

6.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-16       Impact factor: 17.586

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy.

Authors:  Iacopo Olivotto; Barry J Maron; Benedetta Tomberli; Evan Appelbaum; Carol Salton; Tammy S Haas; C Michael Gibson; Stefano Nistri; Eleonora Servettini; Raymond H Chan; James E Udelson; John R Lesser; Franco Cecchi; Warren J Manning; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2013-04-30       Impact factor: 24.094

Review 9.  Lifetime risk: childhood obesity and cardiovascular risk.

Authors:  Julian Ayer; Marietta Charakida; John E Deanfield; David S Celermajer
Journal:  Eur Heart J       Date:  2015-03-24       Impact factor: 29.983

Review 10.  Understanding the process of fibrosis in Duchenne muscular dystrophy.

Authors:  Yacine Kharraz; Joana Guerra; Patrizia Pessina; Antonio L Serrano; Pura Muñoz-Cánoves
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

View more
  4 in total

1.  Early-Onset Late Gadolinium Enhancement is a Prognostic Factor for Duchenne Cardiomyopathy.

Authors:  Lorraine James; Jondavid Menteer; Lilith C Moss; Ramon Durazo-Arvizu; John C Wood; Leigh Ramos-Platt; Emmanuelle Tiongson; Jennifer A Su
Journal:  Pediatr Cardiol       Date:  2022-09-03       Impact factor: 1.838

2.  The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.

Authors:  Molly M Lamb; Bo Cai; Julie Royer; Shree Pandya; Aida Soim; Rodolfo Valdez; Carolyn DiGuiseppi; Katherine James; Nedra Whitehead; Holly Peay; Swamy Y Venkatesh; Dennis Matthews
Journal:  Am J Med Genet A       Date:  2018-09-26       Impact factor: 2.802

Review 3.  The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.

Authors:  Shelagh M Szabo; Renna M Salhany; Alison Deighton; Meagan Harwood; Jean Mah; Katherine L Gooch
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

Review 4.  The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.

Authors:  Dongfang Liu; Saiaditya Badeti; Gianpietro Dotti; Jie-Gen Jiang; He Wang; James Dermody; Patricia Soteropoulos; Deanna Streck; Raymond B Birge; Chen Liu
Journal:  Cell Commun Signal       Date:  2020-08-25       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.